...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Pediatrics >Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study
【24h】

Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study

机译：尽管吸入皮质类固醇药物治疗仍可控制儿童哮喘的炎症表型：PACMAN2研究的原理和设计

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The diagnosis of childhood asthma covers a broad spectrum of pathological mechanisms that can lead to similarly presenting clinical symptoms, but may nonetheless require different treatment approaches. Distinct underlying inflammatory patterns are thought to influence responsiveness to standard asthma medication. Methods/design The purpose of the PACMAN2 study is to identify inflammatory phenotypes that can discriminate uncontrolled childhood asthma from controlled childhood asthma by measures in peripheral blood and exhaled air. PACMAN2 is a nested, case–control follow-up study to the ongoing pharmacy-based “Pharmacogenetics of Asthma medication in Children: Medication with Anti-inflammatory effects” (PACMAN) study. The original PACMAN cohort consists of children aged 4–12?years with reported use of asthma medication. The PACMAN2 study will be conducted within the larger PACMAN cohort, and will focus on detailed phenotyping of a subset of the PACMAN children. The selected participants will be invited to a follow-up visit in a clinical setting at least six months after their baseline visit based on their adherence to usage of inhaled corticosteroids, their asthma symptoms in the past year, and their age (≥ 8?years). During the follow-up visit, current and long-term asthma symptoms, medication use, environmental factors, medication adherence and levels of exhaled nitric oxide will be reassessed. The following measures will also be examined: pulmonary function, exhaled volatile organic compounds, as well as inflammatory markers in peripheral blood and blood plasma. Comparative analysis and cluster-analyses will be used to identify markers that differentiate children with uncontrolled asthma despite their use of inhaled corticosteroids (ICS) (cases) from children whose asthma is controlled by the use of ICS (controls). Discussion Asthmatic children with distinct inflammatory phenotypes may respond differently to anti-inflammatory therapy. Therefore, by identifying inflammatory phenotypes in children with the PACMAN2 study, we may greatly impact future personalised treatment strategies, uncover new leads for therapeutic targets and improve the design of future clinical studies in the assessment of the efficacy of novel therapeutics.
机译：背景技术儿童哮喘的诊断涵盖广泛的病理机制，这些病理机制可能导致类似的临床症状出现，但可能仍需要不同的治疗方法。人们认为不同的潜在炎症模式会影响对标准哮喘药物的反应性。方法/设计PACMAN2研究的目的是通过周围血液和呼气的量度来确定可区分未控制的儿童哮喘与可控制的儿童哮喘的炎症表型。 PACMAN2是一项基于病例对照研究的嵌套式随访研究，该研究正在进行中，以药房为基础的“儿童哮喘的药物遗传学：具有抗炎作用的药物”（PACMAN）研究。最初的PACMAN队列由4-12岁的儿童组成，据报道他们使用了哮喘药物。 PACMAN2研究将在更大的PACMAN队列中进行，并将重点研究PACMAN儿童子集的详细表型。根据参加者对吸入糖皮质激素的使用依从性，过去一年中的哮喘症状和年龄（≥8岁），在基线访问后至少六个月，将邀请选定的参与者进行临床随访。 ）。在随访期间，将重新评估当前和长期的哮喘症状，药物使用，环境因素，药物依从性和呼出一氧化氮的水平。还将检查以下措施：肺功能，呼出的挥发性有机化合物以及外周血和血浆中的炎症标志物。比较分析和聚类分析将用于识别标记，这些标记区分哮喘不受控制的儿童，尽管他们使用吸入性糖皮质激素（ICS）（病例）与哮喘通过控制ICS的儿童（对照）进行比较。讨论具有不同炎症表型的哮喘儿童对抗炎治疗的反应可能不同。因此，通过在PACMAN2研究中确定儿童的炎症表型，我们可能会极大地影响未来的个性化治疗策略，发现治疗靶点的新线索并改善未来临床研究的设计，以评估新疗法的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号